Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for Celldex Therapeutics, Inc. Common Stock, par value $.001 (CLDX).
- Disclosed ownership: 5%.
- Date of event: 03 Apr 2025.
Commodore Capital LP - 03 Apr 2025 SCHEDULE 13G Report for Celldex Therapeutics, Inc. Common Stock, par value $.001 (CLDX)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- COMMODORE CAPITAL LP
- Symbol
- CLDX
- Shares outstanding
- 67,000,000 shares
- Disclosed Ownership
- 3,350,000 shares
- Ownership
- 5%
- Form type
- SCHEDULE 13G
- Filing time
- 10 Apr 2025, 16:05:05 UTC
- Date of event
- 03 Apr 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 5% ownership in Celldex Therapeutics, Inc. Common Stock, par value $.001 (CLDX) on 03 Apr 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 10 Apr 2025, 16:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| COMMODORE CAPITAL LP | 5% | 3,350,000 | 0 | 3,350,000 | /s/ Michael Kramarz | Michael Kramarz, Managing Partner | |
| Commodore Capital Master LP | 5% | 3,350,000 | 0 | 3,350,000 | /s/ Michael Kramarz | Michael Kramarz, Authorized Signatory |